Literature DB >> 1501622

Improved medium with EGF and BSA for differentiated human skeletal muscle cells.

J A St Clair1, S D Meyer-Demarest, R G Ham.   

Abstract

Epidermal growth factor (EGF) and bovine serum albumin (BSA) are both required for serum-free clonal growth of human muscle satellite cells (HMSC). However, neither inhibits differentiation of HMSC, and when both are added to a minimal serum-free differentiation medium, they enhance survival and maintenance of human myotubes. A combination of 10 ng/mL EGF and 0.5 mg/mL BSA, added to MCDB 120 plus 10 micrograms/mL insulin, increases both total protein per dish and total creatine kinase activity, and keeps the myotubes in good condition for a longer period of time. The myotubes become cross-striated and exhibit frequent spontaneous twitching. Substantial amounts of neonatal myosin heavy chain and the MM isozyme of creatine kinase are expressed, together with detectable amounts of adult fast myosin heavy chain. With regular feeding, these cultures can be maintained for at least 3 weeks with no overgrowth by mononucleate cells, and with far less degeneration than with insulin as the only supplement.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501622     DOI: 10.1002/mus.880150705

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

1.  A modified enrichment protocol for adult caprine skeletal muscle stem cell.

Authors:  Ajai K Tripathi; Umed V Ramani; Viral B Ahir; Dharamshi N Rank; Chaitanya G Joshi
Journal:  Cytotechnology       Date:  2010-09-24       Impact factor: 2.058

2.  A tribute to Richard G. Ham (1932-2011).

Authors:  Wallace L McKeehan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-05-12       Impact factor: 2.416

3.  Role of an inward rectifier K+ current and of hyperpolarization in human myoblast fusion.

Authors:  J H Liu; P Bijlenga; J Fischer-Lougheed; T Occhiodoro; A Kaelin; C R Bader; L Bernheim
Journal:  J Physiol       Date:  1998-07-15       Impact factor: 5.182

4.  In vitro expression profiling of myostatin, follistatin, decorin and muscle-specific transcription factors in adult caprine contractile myotubes.

Authors:  A K Tripathi; U V Ramani; D N Rank; C G Joshi
Journal:  J Muscle Res Cell Motil       Date:  2011-03-17       Impact factor: 2.698

5.  Cytokine profiling in patients with VCP-associated disease.

Authors:  Eric Dec; Prachi Rana; Veeral Katheria; Rachel Dec; Manaswitha Khare; Angèle Nalbandian; Szu-Yun Leu; Shlomit Radom-Aizik; Katrina Llewellyn; Lbachir BenMohamed; Frank Zaldivar; Virginia Kimonis
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

6.  Mibefradil (Ro 40-5967) inhibits several Ca2+ and K+ currents in human fusion-competent myoblasts.

Authors:  J H Liu; P Bijlenga; T Occhiodoro; J Fischer-Lougheed; C R Bader; L Bernheim
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  Permanent myopathy caused by mutation of SCN4A Metl592Val: Observation on myogenesis in vitro and on effect of basic fibroblast growth factor on the muscle.

Authors:  Yu Feng; Hong Wang; Xiao-Guang Luo; Yan Ren
Journal:  Neurosci Bull       Date:  2009-04       Impact factor: 5.203

8.  Activation of nicotinic acetylcholine receptors increases the rate of fusion of cultured human myoblasts.

Authors:  R M Krause; M Hamann; C R Bader; J H Liu; A Baroffio; L Bernheim
Journal:  J Physiol       Date:  1995-12-15       Impact factor: 5.182

9.  Contribution of a non-inactivating potassium current to the resting membrane potential of fusion-competent human myoblasts.

Authors:  L Bernheim; J H Liu; M Hamann; C A Haenggeli; J Fischer-Lougheed; C R Bader
Journal:  J Physiol       Date:  1996-05-15       Impact factor: 5.182

10.  Impact of Human Epidermal Growth Factor on Tissue-Engineered Skeletal Muscle Structure and Function.

Authors:  Olga M Wroblewski; Emmanuel E Vega-Soto; Matthew H Nguyen; Paul S Cederna; Lisa M Larkin
Journal:  Tissue Eng Part A       Date:  2021-03-01       Impact factor: 4.080

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.